Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure

Chong, Aun Yeong; Caine, Graham J.; Freestone, Bethan; Blann, Andrew D.; Lip, Gregory Y.H.

doi:10.1016/j.jacc.2003.08.042

Cited by 148 publications

(122 citation statements)

References 30 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Both angiopoietins also correlated with NT-proBNP, but in opposite directions, indicating a compensatory response to cardiac dysfunction. Ang-2 levels have been correlated with acute onset and more severe ischemic CHF, but with normal levels of Ang-1 (Chong et al, 2004).However, in our study, NT-proBNP was the most important prognostic factor. This indicates that NT-proBNP, as a biomarker, captures more of the diversity of factors that influence outcome in AL.…”

Section: Resultscontrasting

confidence: 61%

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

et al. 2010

View full text Add to dashboard Cite

SummarySerum levels of five angiogenic cytokines were evaluated in 82 patients with primary systemic amyloidosis (AL). Angiopoietin-1, vascular endothelial growth factor, basic fibroblast growth factor and angiogenin were higher in AL patients than in controls (n = 35) and newly-diagnosed, symptomatic, myeloma patients (n = 35). Angiopoetin-1/Angiopoetin-2 ratio was lower in AL compared to controls but higher than in myeloma patients. Angiopoetin-2 correlated with cardiac dysfunction indices; however, none of the angiogenic growth factors was prognostically significant. The increased angiogenic cytokine levels observed in AL seem to represent either a toxic effect of amyloid fibrils or light chains, or a compensatory response to organ dysfunction.

show abstract

Section: Resultscontrasting

confidence: 61%

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Ang-2 and VEGF alone are sufficient for the elicitation of angiogenesis, as shown in several studies in different clinical settings. 14,21,22 Therefore, it seems conceivable that our data reflect an association between the profile of angiogenesis markers in CHC and the formation of hepatic neovessels.…”

Section: Discussionmentioning

confidence: 76%

The potential of angiogenesis soluble markers in chronic hepatitis C

et al. 2005

View full text Add to dashboard Cite

Angiogenesis, the formation of new vessels, has been reported to play a significant pathogenic role in liver damage-associated hepatitis C virus infection. Most of our current knowledge derives from immunohistochemical studies of hepatic biopsy samples obtained from chronic hepatitis C (CHC) patients. We evaluated whether CHC is associated with elevated serum levels of angiogenesis markers and whether these are modulated by therapy. Vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), and soluble Tie-2 (sTie-2) were determined in the serum of 36 CHC patients, before and after receiving antiviral combination therapy with pegylated interferon alpha-2b plus ribavirin, and in 15 healthy controls. CHC patients showed elevated baseline VEGF and Ang-2 levels. After treatment, both factors were decreased, whereas antiangiogenic sTie-2 was increased, indicating a shift toward an "anti-angiogenic" profile of serum markers in CHC patients. In conclusion, this suggests that serum VEGF, Ang-2, and sTie-2 levels could be useful as noninvasive, mechanistically based markers of response to therapy and disease progression in CHC. (HEPATOLOGY 2005;42: 696-701.)

show abstract

“…Therefore, additional administration of appropriate therapeutic agents in this period is expected to enhance the ongoing angiogenesis. This is especially relevant since native ANG-1 expression is scarce in ischemic myocardium [33,40], gene transfer of ANG-1 during progressive ischemia period may prove to be useful. This was demonstrated by significant increased microvascular density in the ischemic myocardium of the AdANG-1 group in our study.…”

Section: Discussionmentioning

confidence: 99%

Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model

Shim

Zhang

et al. 2006

J Biomed Sci

View full text Add to dashboard Cite

SummaryThis study investigates the long-term angiogenic effects of ANG-1 and VEGF in a swine chronic myocardial ischemia model. Four-weeks after gradual occlusion of the left circumflex coronary artery by ameroid constrictor, animals were injected with recombinant adenoviral vectors carrying either human ANG-1 (n=9), human VEGF 165 (n=10) or empty vector (n=7) into the left ventricle free wall supplied by the constricted artery. Left ventricular perfusion in animals that received AdANG-1 (3.25±0.16 ml/min/g, p<0.05) recovered robustly 4 weeks after gene transfer while ischemia persisted in the AdVEGF (1.09±0.13 ml/min/ g) and empty vector (1.20±0.03 ml/min/g) groups. Microvascular densities in the left ventricles of animals that received AdANG-1 (19.61±1.76/0.572 mm 2 myocardial tissue, p<0.05) and AdVEGF (18.17±1.43/ 0.572 mm 2 myocardial tissue, p<0.05) were significantly higher than animals that received empty vector (13.53±0.92/0.572 mm 2 myocardial tissue) 12 weeks after gene transfer. ANG-1, but not VEGF, contributed to enhanced regional perfusion by increasing arteriolar density (1.9±0.4/0.572 mm 2 myocardial tissue vs. 0.7±0.2/0.572 mm 2 myocardial tissue, p<0.05) of large-sized (50-100 lm) arterioles. These data demonstrate that gene transfer of ANG-1 and VEGF enhances angiogenesis, but ANG-1 promotes sustained improvement of ventricular perfusion that expedites recovery of ischemic myocardium via arteriogenesis.

show abstract

Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure

Abstract: We have demonstrated abnormal levels of Ang-2 and tie-2, but normal Ang-1, in both CHF patients. These abnormalities may, alongside VEGF, indicate a role for these angiogenic factors in the pathophysiology of CHF.

Cited by 148 publications

References 30 publications

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

The potential of angiogenesis soluble markers in chronic hepatitis C

Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model

Contact Info

Product

Resources

About